Your browser doesn't support javascript.
loading
Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response.
Béguelin, Wendy; Teater, Matt; Meydan, Cem; Hoehn, Kenneth B; Phillip, Jude M; Soshnev, Alexey A; Venturutti, Leandro; Rivas, Martín A; Calvo-Fernández, María T; Gutierrez, Johana; Camarillo, Jeannie M; Takata, Katsuyoshi; Tarte, Karin; Kelleher, Neil L; Steidl, Christian; Mason, Christopher E; Elemento, Olivier; Allis, C David; Kleinstein, Steven H; Melnick, Ari M.
Afiliação
  • Béguelin W; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY 10021, USA. Electronic address: web2002@med.cornell.edu.
  • Teater M; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY 10021, USA; Institute for Computational Biomedicine, Weill Cornell Medicine, Cornell University, New York, NY 10021, USA.
  • Meydan C; Institute for Computational Biomedicine, Weill Cornell Medicine, Cornell University, New York, NY 10021, USA.
  • Hoehn KB; Department of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.
  • Phillip JM; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY 10021, USA.
  • Soshnev AA; Laboratory of Chromatin Biology and Epigenetics, The Rockefeller University, New York, NY 10065, USA.
  • Venturutti L; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY 10021, USA.
  • Rivas MA; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY 10021, USA.
  • Calvo-Fernández MT; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY 10021, USA.
  • Gutierrez J; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY 10021, USA.
  • Camarillo JM; Department of Chemistry, Molecular Biosciences and the National Resource for Translational and Developmental Proteomics, Northwestern University, Evanston, IL 60208, USA.
  • Takata K; Center for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC V5Z 1L3, Canada.
  • Tarte K; UMR 1236, Université Rennes 1, INSERM, Etablissement Français du Sang, 35043 Rennes, France.
  • Kelleher NL; Department of Chemistry, Molecular Biosciences and the National Resource for Translational and Developmental Proteomics, Northwestern University, Evanston, IL 60208, USA.
  • Steidl C; Center for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC V5Z 1L3, Canada.
  • Mason CE; Institute for Computational Biomedicine, Weill Cornell Medicine, Cornell University, New York, NY 10021, USA; Department of Physiology and Biophysics, Weill Cornell Medicine, Cornell University, New York, NY 10021, USA; The WorldQuant Initiative for Quantitative Prediction, Weill Cornell Medicine, N
  • Elemento O; Institute for Computational Biomedicine, Weill Cornell Medicine, Cornell University, New York, NY 10021, USA; Department of Physiology and Biophysics, Weill Cornell Medicine, Cornell University, New York, NY 10021, USA.
  • Allis CD; Laboratory of Chromatin Biology and Epigenetics, The Rockefeller University, New York, NY 10065, USA.
  • Kleinstein SH; Department of Pathology, Yale School of Medicine, New Haven, CT 06520, USA; Interdepartmental Program in Computational Biology and Bioinformatics, Yale University, New Haven, CT 06511, USA.
  • Melnick AM; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY 10021, USA. Electronic address: amm2014@med.cornell.edu.
Cancer Cell ; 37(5): 655-673.e11, 2020 05 11.
Article em En | MEDLINE | ID: mdl-32396861
ABSTRACT
Follicular lymphomas (FLs) are slow-growing, indolent tumors containing extensive follicular dendritic cell (FDC) networks and recurrent EZH2 gain-of-function mutations. Paradoxically, FLs originate from highly proliferative germinal center (GC) B cells with proliferation strictly dependent on interactions with T follicular helper cells. Herein, we show that EZH2 mutations initiate FL by attenuating GC B cell requirement for T cell help and driving slow expansion of GC centrocytes that become enmeshed with and dependent on FDCs. By impairing T cell help, mutant EZH2 prevents induction of proliferative MYC programs. Thus, EZH2 mutation fosters malignant transformation by epigenetically reprograming B cells to form an aberrant immunological niche that reflects characteristic features of human FLs, explaining how indolent tumors arise from GC B cells.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos B / Transformação Celular Neoplásica / Linfoma de Células B / Linfoma Folicular / Reprogramação Celular / Proteína Potenciadora do Homólogo 2 de Zeste / Mutação Limite: Animals / Female / Humans Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos B / Transformação Celular Neoplásica / Linfoma de Células B / Linfoma Folicular / Reprogramação Celular / Proteína Potenciadora do Homólogo 2 de Zeste / Mutação Limite: Animals / Female / Humans Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article